ESTRO 2025 - Abstract Book

S1998

Clinical - Urology

ESTRO 2025

three risk groups, demonstrating good discriminative ability (p<0.0001) (Figure 2). One- and two-year ADT-free survival rates for the low-risk group (<116 points) were 96% and 87%, compared to 90% and 74% for the intermediate group, and 67% and 46% for the high-risk group (>130 points).

Conclusion: We developed a nomogram-based risk classification system to predict ADT-free survival in hormone-sensitive oligorecurrent prostate cancer, aiding in patient selection for MDT and identifying those who may benefit from early treatment intensification, supporting personalized treatment approaches.

Keywords: Oligometastatic prostate cancer, MDT, nomogram